Partner Headlines - ARNA

  1. Orexigen Therapeutics Gains On Diet Pill Nod From European Committee

    Benzinga
  2. Pharmaceutical Stocks In Play Following Merck/Cubist Deal

    Benzinga
  3. What's Driving Orexigen Therapeutics Higher?

    Benzinga
  4. Benzinga's Top #PreMarket Gainers

    Benzinga
  5. Arena Pharma Reports Q3 EPS Loss $0.05, Revenues Of $8.16M Vs. ...

    Benzinga
  6. Earnings Scheduled For November 3, 2014

    Benzinga
  7. 3 Pharma Companies Fighting Obesity

    Benzinga
  8. Benzinga's Top #PreMarket Gainers

    Benzinga
  9. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  10. Eisai And Arena Pharmaceuticals Announce Publication Of Pooled ...

    Benzinga
  11. Earnings Scheduled For August 1, 2014

    Benzinga
  12. Benzinga's Top #PreMarket Losers

    Benzinga
  13. Markets Marginally Lower Ahead Of Earnings Season

    Benzinga
  14. Arena Pharmaceutical Shares Dive On News CEO Sold 40% Of His ...

    Benzinga
  15. Benzinga's Top #PreMarket Losers

    Benzinga
  16. Events Scheduled for Week of Jun. 16th to Jun. 20th

    Benzinga
  17. FDA delays Orexigen drug

    IBD
  18. Is Arena Pharmaceuticals A Biotech Stock To Watch?

    Benzinga
  19. Orexigen Obesity Drug Decision Delayed By FDA

    IBD
  20. Orexigen Shares Plummet Following FDA Decision; Competition Gets ...

    Benzinga
  21. Arena Pharma Posts Q1 Loss Of $0.12/Share, Misses By ~$0.02/Share

    Benzinga
  22. Earnings Scheduled For May 12, 2014

    Benzinga
  23. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE ...

    Benzinga
  24. Benzinga's Top #PreMarket Losers

    Benzinga
  25. Earnings Scheduled For February 27, 2014

    Benzinga
  26. Bad Earnings Weigh In On Diet Stocks

    Benzinga
  27. Top Trending Tickers On StockTwits For February 14

    Benzinga
  28. #PreMarket Primer: Friday, February 14: A Turnaround

    Benzinga
  29. Arena Pharmaceuticals Announces Filing for Marketing Authorization ...

    Benzinga
  30. Celgene To Release Earnings At J.P. Morgan Event Mon.

    IBD
  31. The Top Five Drug Launches Of 2013

    IBD
  32. (ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance ...

    GuruFocus
  33. Benzinga's Top #PreMarket Gainers

    Benzinga
  34. Market Wrap For November 11: Relative Quiet as Traders and Investors ...

    Benzinga
  35. Market Wrap For November 8: Markets Erase Thursday's Losses; ...

    Benzinga
  36. Arena Pharmaceuticals, Eisai Expand Marketing and Supply Agreement ...

    Benzinga
  37. Nasdaq Leads Stocks Lower; Twitter IPO Opens To 80% Gain

    IBD
  38. How Arena’s “$3 Billion” Belviq Withered

    YCharts
  39. Benzinga's Top #PreMarket Losers

    Benzinga
  40. Market Wrap For Tuesday, October 15: Earnings Reports And White ...

    Benzinga
  41. Mid-Afternoon Market Update: Tumi Holdings Rises Amid Market ...

    Benzinga
  42. Mid-Morning Market Update: Markets Slip; Citigroup Profit Misses ...

    Benzinga
  43. UPDATE: Arena Says Eisai Will Double BELVIQ Sales Force to 4 ...

    Benzinga
  44. Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and ...

    Benzinga
  45. Obesity Drug Stocks Jump As Cowen Gets Bullish

    IBD
  46. Benzinga's Top Pre-Market Losers

    Benzinga
  47. Market Wrap For September 30: Debt Ceiling And Government Shutdown ...

    Benzinga
  48. Mid-Afternoon Market Update: Mellanox Rallies As Market Remains ...

    Benzinga
  49. Mid-Day Market Update: Dow Falls Over 100 Points; Active Network ...

    Benzinga
  50. Mid-Morning Market Update: Markets Open Lower; Cal-Maine Q1 Net ...

    Benzinga
  51. UPDATE: Credit Suisse Lowers PT on Arena Pharmaceuticals Following ...

    Benzinga
  52. Arena Pharma Offers Update on Eisai Launch of BELVIQ, Says Placing ...

    Benzinga
  53. Stocks Hitting 52-Week Lows

    Benzinga
  54. BMO Considers Recent Sales Data on Arena's Belviq, Maintains ...

    Benzinga
  55. CEO Shift Aside, Whose Weight-Loss Pill’s Ahead

    YCharts
  56. Stocks Hitting 52-Week Lows

    Benzinga
  57. Stocks Hitting 52-Week Lows

    Benzinga
  58. Arena Pharma Reports Closing of Phase 1b Clinical Trial for APD811

    Benzinga
  59. Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, ...

    Benzinga
  60. It's Hard to Sell a Pill That Nobody's Heard Of

    YCharts
  61. Weekly Preview: Earnings Season Continues, Fed In Focus, Economic ...

    Benzinga
  62. Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)

    Benzinga
  63. Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)

    Benzinga
  64. Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

    Benzinga
  65. Mid-Afternoon Market Update: Markets All Green, Research in Motion ...

    Benzinga
  66. Mid-Day Market Update: GenCorp Rises, Markets Erasing Losses

    Benzinga
  67. Mid-Morning Market Update: Verizon Misses Big on Earnings, Research ...

    Benzinga
  68. Vivus fell 4.2% to 13.72

    IBD
  69. Vivus Stock Drops On Downgrade; Rival Arena Rises

    IBD
  70. Measuring Social Network Buzz Over Pharma Stocks

    YCharts
  71. Vivus Stock Jumps On Latest Qsymia Shipment Numbers

    IBD
  72. Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)

    Benzinga
  73. Benzinga's Top Pre-Market Gainers

    Benzinga
  74. The Best Small Cap Performers of 2012

    Benzinga
  75. Vivus Soars On Qsymia Anti-Obesity Drug Prescriptions

    IBD
  76. Acadia Pharma Rockets Higher on Study Results

    Benzinga
  77. Vivus Stock Soars As Aetna Adds Qsymia To Coverage

    IBD
  78. Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)

    Benzinga
  79. Arena Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  80. UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT ...

    Benzinga
  81. Vivus Earnings Miss Estimates; Arena Waits In Wings

    IBD
  82. Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)

    Benzinga
  83. Arena Pharmaceuticals Initiates Phase 1 Multiple Dose Clinical ...

    Benzinga
  84. WEEKLY CFO SELLS HIGHLIGHT: QCOM, RA, ARNA, ATU, DGX, MSCC

    GuruFocus
  85. Who Needs Diet and Exercise? Health Plans Cover New Vivus Obesity ...

    YCharts
  86. Vivus Expects EU To Reject Diet Drug, Shares Fall

    IBD
  87. Vivus Dives 11% After Warning EU May Not Back Obesity Drug

    FoxBusiness
  88. Stocks Finish Little Changed with Yahoo (YHOO) and FedEx (FDX) ...

    MarketIntelligenceCenter
  89. All Eyes On Vivus As Weight Loss Drug Hits Market

    YCharts
  90. Short Sellers Shy Away from Biotech Firms

    Benzinga
  91. Benzinga's Top Pre-Market Gainers

    Benzinga
  92. UPDATE: Credit Suisse Initiates Arena Pharmaceuticals at Underperform ...

    Benzinga
  93. Health Care Sector Wrap

    FoxBusiness
  94. Short Interest in Biotech Firms on the Rise

    Benzinga
  95. What Slims Down Fastest After Diet Drugs Are Approved by he FDA? ...

    YCharts
  96. Health Care Sector Wrap

    FoxBusiness
  97. Arena Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  98. Four Investment Options Presented by Obesity and Related Health ...

    YCharts
  99. Biotechs In Motion As New Drug Pipeline Brims

    IBD
  100. Who's Next Facebook? VCs Try Software, Internet Firms

    IBD
Trading Center